AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

UTHR · NASDAQ · Biotechnology

United Therapeutics (UTHR)

Builds pulmonary-hypertension medicines and investigational organ-manufacturing platforms.

$497.59

After hours−0.06 (−0.01%)

At close$497.65(+0.92%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	609	615	678	715	749	736	794	799	800	790	782	783
Cost of revenue	70	71	73	78	83	76	93	88	101	103	133	100
Gross profit	539	544	605	637	666	660	702	711	699	687	648	684
	212	284	249	317	323	302	319	347	309	329	322	353
Research & development	85	151	104	140	104	134	149	134	128	140	138	146
	128	132	144	178	219	163	170	191	182	190	184	175
Selling & marketing	21	24	23	25	21	27	27	31	28	33	29	37
General & administrative	107	108	121	152	199	136	144	160	154	157	155	138
Other expenses	0	0	0	0	0	6	0	22	0	0	0	32
Operating income	327	260	356	320	343	358	383	365	389	358	326	331
	25	35	42	35	46	39	41	44	49	87	−8	42
Interest income	45	51	54	46	50	49	51	51	46	43	42	32
Interest expense	16	15	13	12	10	8	6	7	3	3	3	3
Other non-operating income	0	−50	−56	−47	−56	−47	−35	−51	−52	−90	5	−45
Income before tax	352	295	399	355	389	397	424	408	438	444	318	373
Income tax expense	84	78	92	77	80	95	101	99	99	80	43	40
Net income from continuing operations	268	217	307	278	309	301	322	310	339	364	275	333
Net income	268	217	307	278	309	301	322	310	339	364	275	333
EPS, basic	$5.71	$4.62	$6.52	$6.26	$6.93	$6.74	$7.18	$6.86	$7.73	$8.36	$6.32	$7.82
EPS, diluted	$5.38	$4.36	$6.17	$5.85	$6.39	$6.19	$6.63	$6.41	$7.16	$7.66	$5.82	$7.27
Weighted average shares, basic	47	47	47	44	45	45	45	45	44	44	44	43
Weighted average shares, diluted	50	50	50	48	48	49	49	48	47	48	47	46
EBITDA	340	324	427	386	418	424	437	437	463	470	344	376
Depreciation & amortization	13	14	15	19	19	20	20	21	22	23	23	0
EBIT	327	311	412	367	399	404	417	416	441	447	321	376